Medtronic plc filings document material events, capital structure, registered securities, governance matters, and operating and financial disclosures for a medical-device company organized in Ireland. The 8-K record identifies MDT ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, alongside current reports used for company events and financial-result communications.
The filing record also includes exchange and registration status for debt securities, including a Form 25 notice tied to removal from listing and registration of a guarantor class of senior notes. These disclosures frame Medtronic's public-company obligations around equity, debt instruments, material agreements, and regulatory or clinical developments.
Medtronic plc (MDT) intends to accept 55,032,401 Medtronic ordinary shares in its oversubscribed exchange offer for 252,813,348 shares of MiniMed Group, Inc. common stock, at 4.5939 MiniMed shares per accepted Medtronic share. A total of 298,024,452 Medtronic shares were validly tendered and not withdrawn.
The preliminary proration estimate is approximately 18.3%, assuming guaranteed-delivery shares are delivered; Medtronic expects to announce the final factor on October 14, 2026. After completion, Medtronic will retain no outstanding MiniMed shares.
Medtronic plc set the final exchange ratio at 4.5939 MiniMed shares for each Medtronic ordinary share accepted in its offer for up to 225,361,295 newly issued MiniMed shares. That amount represents approximately 80.1% of MiniMed shares outstanding as of September 3, 2026. Tenders may be prorated if the offer is oversubscribed.
If oversubscribed, Medtronic may, without extending the offer period, exchange up to an additional 27,452,053 MiniMed shares for additional Medtronic shares not exceeding two percent of total outstanding Medtronic ordinary shares. The stated estimates are approximately 49,056,639 Medtronic shares accepted with no additional acceptance, or approximately 55,032,401 if Medtronic accepts the additional shares under the stated maximum-increase assumption.
Medtronic plc set the final exchange ratio at 4.5939 MiniMed common shares for each Medtronic ordinary share accepted, with up to 225,361,295 MiniMed shares in the exchange offer. If oversubscribed, Medtronic currently intends to exchange all its remaining MiniMed interest, an additional 27,452,053 shares, without extending the offer period.
The offer and withdrawal rights expire at 12:00 midnight, New York City time, at the end of October 9, 2026, unless extended or terminated. Oversubscription makes the exchange subject to proration.